Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]

• 2020
• Press releases

Tags: AsiDNA™

10/22/2020

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]

• 2020
• Press releases

Tags: AsiDNA™

10/21/2020

Publication of the 2020 Half-Yearly Financial Report

Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

• 2020
• Press releases

09/29/2020

Onxeo reports its financial results for the first half of 2020 and provides an update on its activities

The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]

• 2020
• Financials and Corporate
• Press releases

09/17/2020

Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020

Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

• 2020
• Press releases

09/08/2020

Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]

• 2020
• Press releases

Tags: AsiDNA™

09/03/2020

Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer

DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]

• 2020
• AsiDNA™
• Press releases

Tags: AsiDNA™

08/27/2020

Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility

Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

• 2020
• Financial information
• Press releases

07/29/2020

Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux

July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]

• 2020
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

07/03/2020

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

• 2020
• OX401
• Press releases

Tags: OX401

06/25/2020